Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

Subjects:

MVK activates microglia and decreases phagocytosis. by Ren Y. Sato (16914027)

rhMG53 decreases membrane damage <i>in vitro</i>. by Brian J. Paleo (8694246)

rRL-KD treatment decreased inflammation after MSU-induced acute gout arthritis. by Fábio Mambelli (10005409)

Decrease in circulating iNKT cell activation during regadenoson (RA) infusion into patients with COVID-19. by Joseph Rabin (7399436)

Subjects:

Homozygous deletion of <i>ERG251</i> leads to the decreased ergosterol accumulation in the absence of FLC and decreased production of toxic dienol in the presence of FLC. by Xin Zhou (54275)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Initiation of corticosteroid therapy resulted in a decrease in IP-10 levels (ICU patients, n = 12). by Shaul Lev (779105)

Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment. by Luca G. Valente (12463057)

Short-term depression decreases memory retention. by Alexander Seeholzer (6615989)

Post-losartan treatment prevented SARS-CoV-2 spike protein-induced decreased cognitive impairment but not pre-losartan treatment. by Mackenzi Meier (19251139)

Determinants of decrease in COVID-19 immunity among vaccinated patients over a 6-month period using univariate analysis and multivariable logistic regression models. by Dalal Nour (18530615)

“…<p>Determinants of decrease in COVID-19 immunity among vaccinated patients over a 6-month period using univariate analysis and multivariable logistic regression models.…”

Summary of findings table for the comparison remdesivir 10 days vs. placebo for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Methyl Gallate (MG) treatment decreases hepatocellular carcinoma (HCC) cell survival. by Chien-Yu Huang (802982)

Summary of findings table for the comparison remdesivir 5 days vs. standard of care for hospitalized, moderate COVID-19. by Alejandro Piscoya (782326)

Subjects:

Summary of findings table for the comparison of remdesivir 5 days vs. remdesivir 10 days for hospitalized, severe COVID-19. by Alejandro Piscoya (782326)

Subjects:

Flowchart of study selection. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on invasive ventilation at 14 days. by Alejandro Piscoya (782326)

Subjects:

Effect of remdesivir on all-cause mortality at 14 days. by Alejandro Piscoya (782326)

Subjects:

Description of characteristics of included studies. by Alejandro Piscoya (782326)

Subjects: